WilmerHale Advises Generation Bio in Initial Public Offering

WilmerHale Advises Generation Bio in Initial Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On June 16, 2020, Generation Bio, an innovative genetic medicines company creating a new class of gene therapy, announced the closing of its initial public offering. The company sold 12,105,263 shares of its common stock at a public offering price of $19.00 per share, reflecting the full exercise of the underwriters’ option to purchase additional shares, for aggregate gross proceeds of approximately $230 million, before deducting underwriting discounts and commissions and estimated offering expenses. The shares are listed on the Nasdaq Global Select Market (GBIO). J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company LLC acted as joint book running managers and Wedbush PacGrow acted as lead manager of the offering.

The deal team representing Generation Bio was led by Stuart Falber and Molly Fox.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel